CBMG Cellular Biomedicine Group Inc

Cellular Biomedicine Group Appoints CAR-T Pioneer Dr. Stephan A. Grupp as Member of Scientific Advisory Board

Cellular Biomedicine Group Appoints CAR-T Pioneer Dr. Stephan A. Grupp as Member of Scientific Advisory Board

SHANGHAI, China and NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- . (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the appointment of Dr. Stephan A. Grupp, a CAR-T pioneer and pediatric oncologist, to CBMG’s Scientific Advisory Board to impart scientific vigor and clinical guidance in the Company’s immuno-oncology pipeline.  

“Dr. Grupp is a world-renowned pediatric oncologist and cancer researcher. His decades of work and achievements have had a significant impact on the groundbreaking field of CAR-T therapy,” commented Tony (Bizuo) Liu, Chief Executive Officer for the Company. “He will advise us on our scientific and clinical studies for pediatric and hematologic related cancers. Dr. Grupp joins our team of seasoned scientific advisors, whose expertise, along with CBMG’s solid pre-clinical work and world-class manufacturing processes will advance the development of these transformative therapies.”

About Dr. Grupp

Dr. Stephan A. Grupp, M.D., Ph.D., has been Chief of Section - Cellular Therapy and Transplant in Oncology Division at The Children's Hospital of Philadelphia (CHOP) since June 1, 2017. Dr. Grupp has researched and led groundbreaking clinical trials of CD19-directed CAR-T cell therapy for children with acute lymphoblastic leukemia (ALL). He serves as Medical Director of the Stem Cell Laboratory at CHOP. He has been an attending physician and oncology researcher at CHOP since 1996, and is a Professor of Pediatrics and the University of Pennsylvania Perelman School of Medicine.

Dr. Grupp’s outstanding contribution to oncology is in the clinical development of chimeric antigen receptor CAR T cell (CAR-T) therapy for relapsed and refractory ALL in children and young adults. He is the Director of the Cancer Immunotherapy Program and Director of Translational Research for the Center for Childhood Cancer Research. Working with U Penn Cancer Center, he did many of the preclinical in vivo studies and then developed the first pediatric trial and treated the first pediatric patient at CHOP with CAR-T cell therapy in 2012.

Dr. Grupp completed his clinical training in pediatrics and pediatric hematology/oncology at Boston Children's Hospital, Dana Farber Cancer Institute and Harvard Medical School, performing postdoctoral research in immunology at Harvard. He joined the University of Pennsylvania medical faculty in 1996. He earned his MD and a PhD in Immunology from the University of Cincinnati. Dr. Grupp has published numerous papers on various therapies for the treatment of children with cancers, including CAR-T therapies, and has been honored by numerous prestigious organizations for his work, including the American Society of Pediatric Hematology/Oncology, the University of Pennsylvania Osler Award for patient-oriented research, and the European Society for Blood and Bone Marrow Transplantation.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. (NASDAQ: ) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of 12 independent cell production lines, are designed and managed according to both China and U.S. GMP standards.  Our Shanghai facility includes a ”Joint Laboratory of Cell Therapy” with GE Healthcare and a “Joint Cell Therapy Technology Innovation and Application Center” with Thermo Fisher Scientific, whose partnerships focus on improving manufacturing processes for cell therapies. The CBMG pipeline includes preclinical compounds targeting CD20-, CD22- and B-cell maturation antigen (BCMA)-specific CAR-T compounds, and T-cell receptor (TCR) and tumor infiltrating lymphocyte (TIL) technologies. A Phase IIb trial in China for Rejoin®  autologous Human Adipose-derived Mesenchymal Progenitor Cell (haMPC) for the treatment of Knee Osteoarthritis (KOA) as well as a Phase I trial in China for AlloJoin™ (CBMG’s “Off-the-Shelf” haMPC) for the treatment of KOA are ongoing. CBMG is included in the broad-market Russell 3000® Index and the small-cap Russell 2000® Index, and the Loncar China BioPharma index. To learn more about CBMG, please visit .

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement our plans, strategies and objectives for future operations, including regulatory approval of our IND applications, our plan to configure part of our Shanghai facility with GE Healthcare’s FlexFactory platform, our ability to execute on our obligations under the terms of our licensing and collaboration arrangement with Novartis, our ability to execute on proposed new products, services or development thereof, results of our clinical research and development, regulatory infrastructure governing cell therapy and cellular biopharmaceuticals, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, our ability to seek intellectual property rights for our product candidates, competition in the industry in which we operate, overall market conditions, any statements or assumptions underlying any of the foregoing and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as “may,” “will,” “expects,” “plans,” “intends,” “estimates,” “potential,” or “continue,” or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law. 

Contact:

Derrick C. Li

Head of Strategy and Investor Relations, CBMG



 

 

EN
18/12/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellular Biomedicine Group Inc

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

LUV SOUTHWEST AIRLINES CO
UFI UNIFI INC
PAG PENSKE AUTOMOTIVE GROUP INC
URI UNITED RENTALS INC.
STT STATE STREET CORPORATION
SWK STANLEY BLACK & DECKER INC.
HZO MARINEMAX INC.
ZION ZIONS BANCORPORATION N.A.
WAL WESTERN ALLIANCE BANCORP
URBN URBAN OUTFITTERS INC.
THC TENET HEALTHCARE CORPORATION
TBI TRUEBLUE INC.
RUSHA RUSH ENTERPRISES INC. CLASS A
RM REGIONAL MANAGEMENT CORP
RF REGIONS FINANCIAL CORPORATION
PPBI PACIFIC PREMIER BANCORP INC.
PNFP PINNACLE FINANCIAL PARTNERS INC.
PENN PENN NATIONAL GAMING INC.
PCH POTLATCHDELTIC CORPORATION
PBF PBF ENERGY INC. CLASS A
MNTA MOMENTA PHARMACEUTICALS INC.
DLY LYONDELLBASELL INDUSTRIES NV
LVS LAS VEGAS SANDS CORP.
LBAI LAKELAND BANCORP INC.
JWN NORDSTROM INC.
JBLU JETBLUE AIRWAYS CORPORATION
HAIN HAIN CELESTIAL GROUP INC.
GWB GREAT WESTERN BANCORP INC.
GT GOODYEAR TIRE & RUBBER COMPANY
FSB FRANKLIN FINANCIAL NETWORK INC
FITB FIFTH THIRD BANCORP
FIBK FIRST INTERSTATE BANCSYSTEM INC. CLASS A
FHN FIRST HORIZON CORPORATION
FCF FIRST COMMONWEALTH FINANCIAL CORPORATION
ETN EATON CORP. PLC
EMN EASTMAN CHEMICAL COMPANY
EFSC ENTERPRISE FINANCIAL SERVICES CORP
EBS EMERGENT BIOSOLUTIONS INC.
EAT BRINKER INTERNATIONAL INC.
CUBI CUSTOMERS BANCORP INC.
CENTERSTATE BANK CORPORATION
COLB COLUMBIA BANKING SYSTEM INC.
CMC COMMERCIAL METALS COMPANY
BRKL BROOKLINE BANCORP INC.
AXE ANIXTER INTERNATIONAL INC.
ALNY ALNYLAM PHARMACEUTICALS INC
AEIS ADVANCED ENERGY INDUSTRIES INC.
GNK GENCO SHIPPING & TRADING LTD.
TK TEEKAY CORPORATION
CAT CATERPILLAR INC.
BJRI BJ'S RESTAURANTS INC.
FNB F.N.B. CORPORATION
TILE INTERFACE INC.
MCK MCKESSON CORPORATION
ACLS AXCELIS TECHNOLOGIES INC.
CAH CARDINAL HEALTH INC.
CBPX CONTINENTAL BUILDING PRODUCTS INC.
COHU COHU INC.
EV EATON VANCE CORP.
GEF GREIF CLASS A
HNI HNI CORPORATION
MINI MOBILE MINI INC.
THO THOR INDUSTRIES INC.
TSC TRISTATE CAPITAL HOLDINGS INC
VSH VISHAY INTERTECHNOLOGY INC.
CHRW C.H. ROBINSON WORLDWIDE INC.
SYX SYSTEMAX INC.
5AH PANHANDLE OIL & GAS INC.
JHG JANUS HENDERSON GROUP PLC
MATW MATTHEWS INTERNATIONAL CORPORATION CLASS A
CBMG CELLULAR BIOMEDICINE GROUP INC
DLX DELUXE CORPORATION
ABBV ABBVIE INC.
HOG HARLEY-DAVIDSON INC.
DOW DOW INC.
 PRESS RELEASE

Cellular Biomedicine Group Appoints CAR-T Pioneer Dr. Stephan A. Grupp...

Cellular Biomedicine Group Appoints CAR-T Pioneer Dr. Stephan A. Grupp as Member of Scientific Advisory Board SHANGHAI, China and NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- . (NASDAQ: CBMG) (“CBMG” or the “Company”), a biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the appointment of Dr. Stephan A. Grupp, a CAR-T pioneer and pediatric oncologist, to CBMG’s Scientific Advisory Board to impart scientific vigor and clinical guidance in the Company’s immuno-oncology pipeline.   “Dr. Grupp is ...

 PRESS RELEASE

Cellular Biomedicine Group Reports Third Quarter Financial Results and...

Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent Business Highlights Debuted its next 12-18 months’ immuno-oncology clinical development programs for both hematologic malignancies and solid tumors to key opinion leaders, investment and industry executivesLicensed patents from the National Cancer Institute (“NCI”) to develop the next generation neoantigen-reactive tumor infiltrating lymphocyte (“TIL”) technology to treat a variety of cancersStruck a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymr...

 PRESS RELEASE

Cellular Biomedicine Group to Provide Company Cancer Immunotherapy Pip...

Cellular Biomedicine Group to Provide Company Cancer Immunotherapy Pipeline Update and Facility Tour for Attendees of the Advanced Cell Therapy Summit in Shanghai SHANGHAI, China and CUPERTINO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- . (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell therapies for degenerative diseases, will provide a Company cancer immunotherapy pipeline update and host a tour of its GMP facility for attendees of the Advanced Cell Therapy Summit 2018 in Shanghai on M...

Dr Nathaniel Calloway
  • Dr Nathaniel Calloway

Cellular Biomedicine Group - CBMG and Novartis sign manufacturing part...

Cellular Biomedicine Group (CBMG) announced it has signed an exclusive partnership with Novartis to manufacture the CAR-T therapy Kymriah in China. Novartis retains all marketing responsibility and CBMG will be entitled to both a mark-up on manufacturing costs and an escalating single-digit royalty on sales. Additionally, Novartis will take an equity stake in CBMG of approximately 9%: $40m at $27.43/share. Our valuation is lifted to $535m (from $353.1m).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch